Onset-age of bipolar disorders at six international sites☆
Abstract
Background
Onset-age is a stable characteristic of bipolar disorder (BPD) patients of clinical and probable psychobiological importance, but large pooled clinical samples from multiple sites employing modern diagnostic criteria to quantify onset-age remain rare.
Methods
We pooled diagnostic, demographic, and clinical data from 1566 BPD patients from six international sites (5 European, 1 US) to compare onset-ages in subgroups.
Results
Median
±
IQR onset in 1090 BP-I patients was 5.8 years younger than 476 BP-II cases (24.3
±
18.3 vs. 30.1
±
13.8 years; p
<
0.0001). Onset-age ranked: [a] BP-I men (23.0
±
12.8); [b] BP-I women (26.0
±
14.2); [c] BP-II men (29.7
±
19.1); and [d] BP-II women (30.1
±
17.5 years. Juvenile-onset (≤
age 20) was more common in Europe than the US (27% vs. 16%), as was childhood-onset (<
13 years: 3.3% vs. 0%; both p
<
0.001). Proportion of all cases, and median onset for first episodes ranked: [a] BP-I psychotic (6.3%; 22.7
±
9.2); [b] BP-I manic (29.3%; 24.0
±
12.1); [c] BP-I depressed (25.1%; 24.5
±
14.9); [d] BP-I mixed (9.7%; 27.9
±
16.0); [e] BP-II depressed (26.9%; 30.0
±
19.5); and [f] BP-II hypomanic (2.8%; 33.6
±
15.1 years; p
<
0.0001). Among BP-I patients, onset was similar for various forms of mania and major depression; in BP-II patients initial depression was 9.6-times more frequent and diagnosed earlier than hypomania.
Limitations
There was some variance among sites and only 34.1% of patients were evaluated at onset.
Conclusions
Type I BPD began much earlier than type II; its mainly psychotic presentations occurred earliest, but BP-I men were younger than women, especially at psychotic or mixed onsets.
Keywords: Bipolar I and II disorders, Onset-age
To access this article, please choose from the options below
☆ Disclosures: Dr. Baldessarini has recently been a consultant or investigator-initiated research collaborator with: AstraZeneca, Auritec, Biotrofix, Janssen, JDS-Noven, Lilly, Luitpold, NeuroHealing, Novartis, Pfizer, and SK-BioPharmaceutical Corporation; he is not a member of pharmaceutical speakers' bureaus, nor does he or any family member hold equity positions in biomedical or pharmaceutical corporations. Dr. Perez is a former employee of Eli Lilly Corporation (to 2004). Dr. Tohen was an employee of Eli Lilly & Co (to 2008), and is a consultant or has received speaker's honoraria from Astra-Zeneca, BristolMyers-Squibb, Eli Lilly, Glaxo-SmithKline, Johnson & Johnson and Wyeth Corporations; his spouse is an Eli Lilly employee and stockholder. Dr. Vieta has served as a consultant or speaker for Astra-Zeneca, BristolMyers-Squibb, Eli Lilly, Forest Research Institute, Glaxo-Smith-Kline, Janssen-Cilag, Jazz, Lundbeck, Merck, Novartis, Organon, Otsuka, Pfizer, Sanofi-Aventis, Servier, Shering-Plough, United Biosource, and Wyeth Corporations. Other authors have no relevant disclosures of potential conflicts of interest.
PII: S0165-0327(09)00253-5
doi:10.1016/j.jad.2009.05.030
© 2009 Elsevier B.V. All rights reserved.
